Drug Eruptions AND Severe Cutaneous Adverse Reactions

The answer first

Drug Eruptions AND Severe Cutaneous Adverse Reactions is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Drug Eruptions AND Severe Cutaneous Adverse Reactions to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Takada T Antithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches Cureus, 2026.PMID 42465709
2. [2]Srisuwatchari W, Norchai P Hypersensitivity reactions associated with nutraceuticals and dietary supplements: A narrative review Asian Pac J Allergy Immunol, 2026.PMID 42437383
3. [3]Mullan KA, Davies S, Teoh K, Tucker HL, et al. Immunological and molecular signatures of carbamazepine-induced maculopapular exanthema Front Immunol, 2026.PMID 42433382
4. [4]Omran S, Gan SH, Teoh SL Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions Eur J Hum Genet, 2026.PMID 40993225
5. [5]Wu PC, Chen WT, Huang IH, Chen CB, et al. Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis JAMA Dermatol, 2024.PMID 38568509
6. [6]Asgarpour JMS, Lam LM, Vogel TK, Goez HR, et al. Human Leukocyte Antigen Gene Testing and Carbamazepine-Induced Toxic Epidermal Necrolysis: A Study of Pediatric Practice J Cutan Med Surg, 2021.PMID 32909461
7. [7]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
8. [8]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005
9. [9]Osborne AK, Brown RD, Sillence E Effects of Social Media Narratives on Affective and Behavioral Responses to Menopause Content: Randomized Online Experimental Study JMIR Form Res, 2026.PMID 42467962
10. [10]Bayrak Durmaz MS, Akın BG, Kalkan F, Öztürk BÖ, et al. Delayed-type drug hypersensitivity reactions in a tertiary adult allergy clinic: A 5-year cohort study Allergol Immunopathol (Madr), 2026.PMID 42433045
11. [11]O'Kelly SL, Deane EM, Halpern SM Pembrolizumab-induced severe eczematous dermatitis and the use of methotrexate as a steroid-sparing agent BMJ Case Rep, 2026.PMID 42425603
12. [12]Guzmán M, Millán R, Ramírez C, Ibáñez S, et al. [Clinical Characterization of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at a Tertiary Hospital in Chile between 2014 and 2021] Rev Med Chil, 2026.PMID 42441676